KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Invested Capital (2016 - 2025)

Pfizer (PFE) has disclosed Invested Capital for 17 consecutive years, with $4.3 billion as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 95.39% to $4.3 billion in Q3 2025 year-over-year; TTM through Dec 2025 was $4.3 billion, a 95.16% decrease, with the full-year FY2024 number at $89.0 billion, down 10.7% from a year prior.
  • Invested Capital was $4.3 billion for Q3 2025 at Pfizer, down from $89.9 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $105.4 billion in Q2 2023 to a low of $4.3 billion in Q3 2025.
  • A 5-year average of $85.0 billion and a median of $89.9 billion in 2025 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: grew 27.5% in 2023, then tumbled 95.39% in 2025.
  • Pfizer's Invested Capital stood at $78.3 billion in 2021, then rose by 23.5% to $96.7 billion in 2022, then increased by 3.03% to $99.6 billion in 2023, then dropped by 10.7% to $89.0 billion in 2024, then tumbled by 95.16% to $4.3 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Invested Capital are $4.3 billion (Q3 2025), $89.9 billion (Q2 2025), and $95.1 billion (Q1 2025).